The drug semaglutide is already widely used for weight loss. Now its maker is presenting new evidence that it can reduce cardiovascular illnesses and deaths.
More than half the world’s population is expected to be overweight or obese by 2035. Excess weight is often linked with cardiovascular disease: It can lead to higher blood pressure or cholesterol, which increases the risk of heart attack and stroke. Now, the makers of the popular weight-loss drug Wegovy are making a case for its use as a treatment option for diseases of the heart and blood vessels.
But what the trial investigators were most interested in was whether semaglutide could reduce the risk of major cardiovascular events. During the study, 234 patients in the semaglutide group experienced a nonfatal heart attack, and 154 had a nonfatal stroke, compared with 322 and 165 in the placebo group, respectively. Out of those taking semaglutide, 97 were hospitalized or visited an urgent care clinic for heart failure, compared with 122 taking a placebo.
Weight-Loss Drug Wegovy Treatment Cardiovascular Diseases Obesity Overweight Blood Pressure Cholesterol Heart Attack Stroke
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk's Weight-Loss Drug Wegovy Reduces Cardiovascular Risk in Non-Diabetic PatientsClosely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say
Read more »
FDA Approves New Weight Loss Drug That Slashes Patients' Weight by 18%Digital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »
FDA Approves New Weight Management Drug Zepbound as Rival to WegovyEli Lilly is about to release Zepbound, a new entrant in the superheated competition for blockbuster weight loss drugs.
Read more »
New Version of Diabetes Medication Approved as Weight Loss DrugZepbound es el más reciente medicamento contra la diabetes aprobado para la pérdida de peso, y se une a Wegovy, de Novo Nordisk, una versión en dosis altas de su tratamiento contra la diabetes Ozempic.
Read more »
Eli Lilly’s new weight loss drug could drive down rivals' pricesThe Danish drugmaker’s Zepbound will undercut its rivals’ pricing by 21% but still cost over $1,000 a month.
Read more »
Eli Lilly's Weight-Loss Drug Costs Less Than Wegovy. Here's Why.Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.
Read more »